Scarica l'app Stockscreener
60.36
4.79%
2.76
Dopo l'orario di chiusura:
60.69
0.33
+0.55%
Precedente Chiudi:
$57.60
Aprire:
$58.57
Volume 24 ore:
335.12K
Relative Volume:
1.27
Capitalizzazione di mercato:
$403.36M
Reddito:
-
Utile/perdita netta:
$-19.44M
Rapporto P/E:
-17.55
EPS:
-3.4389
Flusso di cassa netto:
$-10.83M
1 W Prestazione:
+4.77%
1M Prestazione:
+8.84%
6M Prestazione:
+22.63%
1 anno Prestazione:
+104.68%
Intervallo 1D:
$58.25
$61.03
Intervallo di 1 settimana:
$53.94
$61.03
Portata 52W:
$26.05
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
60.36 | 403.36M | 0 | -19.44M | -10.83M | -3.4389 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-09 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Iniziato | Leerink Partners | Outperform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-09 | Iniziato | BTIG Research | Buy |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-08-26 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
(MNPR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
Published on: 2026-03-07 04:32:52 - baoquankhu1.vn
Monopar Therapeutics (MNPR) officer Susan Rodriguez submits initial Form 3 - Stock Titan
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez - The Globe and Mail
MNPR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Monopar names Susan Rodriguez as chief commercial officer - Investing.com India
Responsive Playbooks and the MNPR Inflection - Stock Traders Daily
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer - Bitget
Monopar expands leadership team with appointment of seasoned biopharma executive Susan Rodriguez as chief commercial and strategy officer - marketscreener.com
New Monopar (NASDAQ: MNPR) strategy chief to steer ALXN1840 NDA - Stock Titan
Monopar Therapeutics Inc. Appoints Susan Rodriguez as Chief Commercial and Strategy Officer, Effective from March 2, 2026 - marketscreener.com
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
BTIG Reiterates Buy Rating for MNPR with $104 Target Price | MNP - GuruFocus
Monopar Therapeutics (NASDAQ:MNPR) Earns Buy Rating from BTIG Research - MarketBeat
Is Monopar Therapeutics Inc. stock ready for breakoutWeekly Trading Summary & Accurate Intraday Trade Tips - mfd.ru
Can Monopar Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Short Interest & Trade Opportunity Analysis Reports - mfd.ru
Retail Trends: Will Monopar Therapeutics Inc benefit from sector rotationPrice Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Understanding the Setup: (MNPR) and Scalable Risk - Stock Traders Daily
RA Capital reports 9.99% Monopar Therapeutics stake in Schedule 13G/A (MNPR) - Stock Titan
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Monopar Therapeutics (NASDAQ:MNPR) Head to Head Comparison - Defense World
Why Monopar Therapeutics Inc. (1IY0) stock attracts wealthy investors2025 Bull vs Bear & Stepwise Entry and Exit Trade Signals - mfd.ru
MNPR PE Ratio & Valuation, Is MNPR Overvalued - Intellectia AI
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Should I add Monopar Therapeutics Inc. stock to my portfolio2025 Retail Activity & AI Based Trade Execution Alerts - mfd.ru
Stocks showing improved relative strength: Monopar Therapeutics - MSN
The Technical Signals Behind (MNPR) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 21.1% - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at BTIG Research - Defense World
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease - TipRanks
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Bull Bear: Why is Monopar Therapeutics Inc stock going down2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Precision Trading with Monopar Therapeutics Inc. (MNPR) Risk Zones - Stock Traders Daily
Breakout Move: Will Monopar Therapeutics Inc outperform tech stocksStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Market Leaders: Will Monopar Therapeutics Inc outperform tech stocksMarket Rally & Growth Focused Entry Reports - baoquankhu1.vn
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
Monopar Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Monopar Therapeutics: Tiny Cancer-Drug Stock Caught Between Speculation And Survival - AD HOC NEWS
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December - MarketBeat
Fundamentals Check: Why is Monopar Therapeutics Inc stock going downJuly 2025 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Technical Reactions to MNPR Trends in Macro Strategies - Stock Traders Daily
Price Action: Is Monopar Therapeutics Inc impacted by rising rates2025 Risk Factors & Short-Term High Return Ideas - baoquankhu1.vn
History Review: Is CO2 Energy Transition Corp a stock for growth or value investors2025 Geopolitical Influence & High Win Rate Trade Tips - baoquankhu1.vn
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):